Drug Trial Radar · NCT07543224
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis.
Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Apr 2026
Primary completion
Jan 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Reistone Biopharma Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Apr 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase III Efficacy and Safety Study of RSS0393 Ointment in Plaque Psoriasis.
Conditions
- Plaque Psoriasis Subjects
Interventions
RSS0393 ointment 0.03%Drug
RSS0393 ointment 0.03%
RSS0393 ointment placeboDrug
RSS0393 ointment placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Achieving a Physician's Global Assessment (PGA) response at Week 8Time frame: week8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital (PUMCH)
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.